J
Jane Estell
Researcher at Concord Hospital
Publications - 31
Citations - 1848
Jane Estell is an academic researcher from Concord Hospital. The author has contributed to research in topics: Multiple myeloma & Follicular lymphoma. The author has an hindex of 13, co-authored 28 publications receiving 1549 citations. Previous affiliations of Jane Estell include University of Sydney & Concord Repatriation General Hospital.
Papers
More filters
Journal ArticleDOI
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Gilles Salles,John F. Seymour,Fritz Offner,Armando López-Guillermo,David Belada,Luc Xerri,Pierre Feugier,Reda Bouabdallah,John Catalano,Pauline Brice,Dolores Caballero,Corinne Haioun,Lars Moller Pedersen,Alain Delmer,David Simpson,Sirpa Leppä,Pierre Soubeyran,Anton Hagenbeek,Olivier Casasnovas,Tanin Intragumtornchai,Christophe Fermé,Maria Gomes da Silva,Catherine Sebban,Andrew Lister,Jane Estell,Gustavo Milone,Anne Sonet,Myriam Mendila,Bertrand Coiffier,Hervé Tilly +29 more
TL;DR: 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS.
Journal ArticleDOI
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma : analysis of PET-CT in a subset of PRIMA trial participants.
Judith Trotman,Marion Fournier,Thierry Lamy,John F. Seymour,Anne Sonet,Andrea Janíková,Ofer Shpilberg,Emmanuel Gyan,Hervé Tilly,Jane Estell,Cecily Forsyth,Didier Decaudin,B. Fabiani,Jean Gabarre,Bruno Salles,Eric Van Den Neste,Danielle Canioni,Etienne Garin,Michael J. Fulham,Thierry Vander Borght,Gilles Salles +20 more
TL;DR: PET-CT status at the end of immunochemotherapy induction in patients with FL is strongly predictive of outcome and should be considered a meaningful clinical end point in future studies.
Journal ArticleDOI
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
Emmanuel Bachy,John F. Seymour,Pierre Feugier,Fritz Offner,Armando López-Guillermo,David Belada,Luc Xerri,John Catalano,Pauline Brice,François Lemonnier,Alejandro Martín,Olivier Casasnovas,Lars Møller Pedersen,Véronique Dorvaux,David Simpson,Sirpa Leppä,Jean Gabarre,Maria Gomes da Silva,Sylvie Glaisner,Loic Ysebaert,Anne Vekhoff,Tanin Intragumtornchai,Steven Le Gouill,Andrew Lister,Jane Estell,Gustavo Milone,Anne Sonet,Jonathan Farhi,Harald Zeuner,Hervé Tilly,Gilles Salles +30 more
TL;DR: Rituximab maintenance after induction immunochemotherapy provides a significant long-term PFS, but not OS, benefit over observation, and a final overview of safety is provided.
Journal ArticleDOI
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Emmanuel Bachy,Matthew J. Maurer,Thomas M. Habermann,Bénédicte Gelas-Dore,Delphine Maucort-Boulch,Delphine Maucort-Boulch,Jane Estell,Jane Estell,Eric Van Den Neste,Reda Bouabdallah,Emmanuel Gyan,Andrew L. Feldman,Joan Bargay,Alain Delmer,Susan L. Slager,Maria Gomes da Silva,Olivier Fitoussi,David Belada,Hervé Maisonneuve,Tanin Intragumtornchai,Stephen M. Ansell,Thierry Lamy,Peggy Dartigues,Brian K. Link,John F. Seymour,James R. Cerhan,Gilles Salles +26 more
TL;DR: The PRIMA-PI is a novel and easy-to-compute prognostic index for patients initially treated with immunochemotherapy and could serve as a basis for building more sophisticated and integrated biomolecular scores.
Journal ArticleDOI
Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy
Gilles Salles,John F. Seymour,Pierre Feugier,Fritz Offner,Armando López-Guillermo,David Belada,Luc Xerri,Reda Bouabdallah,John G. Catalano,Brice Pauline,Dolores Caballero,Corinne Haioun,Lars Moller Pedersen,Alain Delmer,David Simpson,Sirpa Leppä,Pierre Soubeyran,Anton Hagenbeek,Olivier Casasnovas,Tanin Intragumtornchai,Christophe Fermé,Maria Gomes da Silva,Catherine Sebban,Andrew Lister,Jane Estell,Gustavo Milone,Anne Sonet,Bertrand Coiffier,Hervé Tilly +28 more
TL;DR: The effect of rituximab maintenance was consistent among patients subgroups categorized by age, sex, FLIPI score category, induction chemotherapy and response to induction, and found to be consistent among these different subgroups.